International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Sep 2007
Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma.
To determine the long-term outcomes after multimodality treatment of retroperitoneal, pelvic, and deep truncal sarcomas and to identify the factors associated with local control (LC), distant metastasis (DM), and overall survival (OS). ⋯ The results of this study emphasize the importance of LC in patients with retroperitoneal sarcoma. Radiation dose escalation or radiosensitization strategies to enhance LC are warranted.
-
Int. J. Radiat. Oncol. Biol. Phys. · Aug 2007
Clinical TrialIntensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures.
To present initial results of a clinical trial of intensity-modulated radiotherapy (IMRT) aiming to spare the swallowing structures whose dysfunction after chemoradiation is a likely cause of dysphagia and aspiration, without compromising target doses. ⋯ These dose-volume-effect relationships provide initial IMRT optimization goals and motivate further efforts to reduce swallowing structures doses to reduce dysphagia and aspiration.
-
Int. J. Radiat. Oncol. Biol. Phys. · Aug 2007
Randomized Controlled Trial Multicenter StudyNeurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone.
To determine how the omission of whole brain radiotherapy (WBRT) affects the neurocognitive function of patients with one to four brain metastases who have been treated with stereotactic radiosurgery (SRS). ⋯ The results of the present study have revealed that, for most brain metastatic patients, control of the brain tumor is the most important factor for stabilizing neurocognitive function. However, the long-term adverse effects of WBRT on neurocognitive function might not be negligible.
-
Int. J. Radiat. Oncol. Biol. Phys. · Aug 2007
Randomized Controlled Trial Multicenter StudyIsotope and patient age predict for PSA spikes after permanent prostate brachytherapy.
To evaluate prostate-specific antigen (PSA) spikes after permanent prostate brachytherapy in low-risk patients. ⋯ In low-risk prostate cancer, PSA spikes are most common in patients implanted with (125)I and/or <65 years of age. Differences in isotope-related spikes are most pronounced in hormone-naive patients.